Expert Opinion on Investigational Drugs

Aims & Scope

Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.

The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.1
2024	4.90

SJR (SCImago Journal Rank)

Year	Value
2024	1.267

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	122

Journal Rank

Year	Value
2024	3223

Journal Citation Indicator

Year	Value
2024	1336

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

  Citation: 527

  Authors: Dev, Robert, Gaurav, Jiong, Marwan

• Glioblastoma multiforme: a review of where we have been and where we are going

  Citation: 405

  Authors: Cory, Okezie O, Ankit I, Chunhui, Ningjing, Austin K, Darell D

• Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment

  Citation: 360

  Authors: Jamie S, David W

• The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  Citation: 356

  Authors: Hae-Young, Min-Soo, Aree

• Targeting STAT3 in cancer: how successful are we?

  Citation: 342

  Authors: Peibin, James

• Rutin: therapeutic potential and recent advances in drug delivery

  Citation: 327

  Authors: Shrestha, Asgar, Javed, Jasjeet K., Sanjula

• Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

  Citation: 285

  Authors: Madeleine, Jenny

• Terpenoids: natural products for cancer therapy

  Citation: 271

  Authors: Min, Jin-Jian, Ming-Qing, Jiao-Lin, Xiu-Ping, Yi-Tao

• Therapeutic applications of carbon monoxide-releasing molecules

  Citation: 265

  Authors: Roberto, Brian E, Roberta

• Berberine: a potential phytochemical with multispectrum therapeutic activities

  Citation: 261

  Authors: Parameswara Rao, Subhashis, Sanjay

---